Education
About Us
Working with TipRanks
Follow Us
Guard Therapeutics International AB (DE:5LH0)
FRANKFURT:5LH0
Total Valuation
Guard Therapeutics International AB has a market cap or net worth of €3.00M. The enterprise value is -€15.54M.
Market Cap€3.00M
Enterprise Value-€15.54M
Share Statistics
Guard Therapeutics International AB has 20,167,631 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding20,167,631
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Guard Therapeutics International AB’s return on equity (ROE) is -2.68 and return on invested capital (ROIC) is -244.62%.
Return on Equity (ROE)-2.68
Return on Assets (ROA)-2.01
Return on Invested Capital (ROIC)-244.62%
Return on Capital Employed (ROCE)-2.45
Revenue Per Employee0.00
Profits Per Employee-9.07M
Employee Count12
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Guard Therapeutics International AB is ―. Guard Therapeutics International AB’s PEG ratio is 0.00814.
PE Ratio―
PS Ratio0.00
PB Ratio0.65
Price to Fair Value0.65
Price to FCF0.00
Price to Operating Cash Flow-0.29
PEG Ratio0.00814
Income Statement
In the last 12 months, Guard Therapeutics International AB had revenue of 0.00 and earned -108.85M in profits. Earnings per share was -6.04.
Revenue0.00
Gross Profit0.00
Operating Income-107.74M
Pretax Income-108.85M
Net Income-108.85M
EBITDA-107.74M
Earnings Per Share (EPS)-6.04
Cash Flow
In the last 12 months, operating cash flow was -116.98M and capital expenditures 0.00, giving a free cash flow of -116.98M billion.
Operating Cash Flow-116.98M
Free Cash Flow-116.98M
Free Cash Flow per Share-5.80
Dividends & Yields
Guard Therapeutics International AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.21
52-Week Price Change-96.74%
50-Day Moving Average0.06
200-Day Moving Average1.04
Relative Strength Index (RSI)43.57
Average Volume (3m)0.00
Important Dates
Guard Therapeutics International AB upcoming earnings date is May 13, 2026, TBA (Confirmed).
Last Earnings DateFeb 20, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
Guard Therapeutics International AB as a current ratio of 5.36, with Debt / Equity ratio of 0.00%
Current Ratio5.36
Quick Ratio5.36
Debt to Market Cap0.00
Net Debt to EBITDA0.46
Interest Coverage Ratio-48.25
Taxes
In the past 12 months, Guard Therapeutics International AB has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Guard Therapeutics International AB EV to EBITDA ratio is 0.22, with an EV/FCF ratio of 0.00.
EV to Sales0.00
EV to EBITDA0.22
EV to Free Cash Flow0.00
EV to Operating Cash Flow0.21
Balance Sheet
Guard Therapeutics International AB has €100.48M in cash and marketable securities with €0.00 in debt, giving a net cash position of €100.48M billion.
Cash & Marketable Securities€100.48M
Total Debt€0.00
Net Cash€100.48M
Net Cash Per Share€4.98
Tangible Book Value Per Share€2.25
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Guard Therapeutics International AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―